# Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery (ERICCA study): a multicentre double-blind randomised controlled clinical trial

Derek J Hausenloy,<sup>1,2,3,4\*†</sup> Luciano Candilio,<sup>1†</sup> Richard Evans,<sup>5</sup> Cono Ariti,<sup>5</sup> David P Jenkins,<sup>6</sup> Shyamsunder Kolvekar,<sup>7</sup> Rosemary Knight,<sup>5</sup> Gudrun Kunst,<sup>8</sup> Christopher Laing,<sup>9</sup> Jennifer M Nicholas,<sup>5</sup> John Pepper,<sup>10</sup> Steven Robertson,<sup>5</sup> Maria Xenou,<sup>1</sup> Timothy Clayton<sup>5</sup> and Derek M Yellon<sup>1,2</sup>

- <sup>1</sup>Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, UK
- <sup>2</sup>National Institute for Health Research, University College London Hospitals Biomedical Research Centre, London, UK
- <sup>3</sup>National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore
- <sup>4</sup>Cardiovascular and Metabolic Disorders Program, Duke–National University of Singapore, Singapore
- <sup>5</sup>Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK <sup>6</sup>Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, UK
- <sup>7</sup>The Heart Hospital, University College London Hospitals NHS Foundation Trust, London, UK
- <sup>8</sup>Department of Anaesthetics and Pain Therapy, King's College London and King's College Hospital, London, UK
- <sup>9</sup>University College London Centre for Nephrology, Royal Free Hospital, London, UK
- <sup>10</sup>National Institute for Health Research Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust, London, UK

### \*Corresponding author

†Derek J Hausenloy and Luciano Candilio are joint first authors

**Declared competing interests of authors:** Derek J Hausenloy and Timothy Clayton report grants from the British Heart Foundation during the conduct of the study.

Published June 2016 DOI: 10.3310/eme03040

# **Plain English summary**

## The ERICCA study

Efficacy and Mechanism Evaluation 2016; Vol. 3: No. 4 DOI: 10.3310/eme03040

NIHR Journals Library www.journalslibrary.nihr.ac.uk

# **Plain English summary**

Coronary heart disease (CHD) is the leading cause of death in the UK, accounting for 124,000 deaths in 2006 and costing the UK economy over £7.9B per year. Patients with severe CHD are usually treated by an operation called coronary artery bypass graft (CABG) surgery. This operation can carry risks, particularly in sicker patients. New treatment strategies are therefore required to improve the outcome and recovery of these higher-risk patients undergoing CABG surgery.

The ERICCA (Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery) trial investigated a new method for reducing the damage to the heart muscle during CABG surgery with or without valve surgery. The intervention assessed was remote ischaemic preconditioning (RIPC), which is a low-cost, non-invasive strategy. RIPC consists of placing a blood pressure cuff on the upper arm to temporarily reduce blood flow to the arm. Smaller studies have indicated that reducing the blood flow to the arm for a short period of time can protect internal organs from injury caused by interruption of blood supply, which occurs during major operations such as CABG surgery. The temporary cessation of blood flow to the arm activates a reflex that makes internal organs more resistant to the harmful effects of low blood flow. This reflex is called RIPC.

A total of 1612 patients were recruited from 30 hospitals in the UK. All patients were allocated to receive either RIPC or a 'pretend' procedure (control group). The cuff was inflated continuously on the arm for a 5-minute period and was then deflated for 5 minutes. This was performed four times. The cuff was applied after anaesthetic and before surgery started.

Patients were followed up after 1 year, when information was collected on the primary end point, consisting of a combination of the rate of death, myocardial infarction, stroke and requirement for repeat revascularisation.

We found no difference in the primary end point between patients who received the RIPC intervention and those receiving the intervention simulating RIPC, thereby demonstrating that RIPC provides no additional benefit to patients undergoing CABG surgery with or without valve surgery.

© Queen's Printer and Controller of HMSO 2016. This work was produced by Hausenloy *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

# **Efficacy and Mechanism Evaluation**

ISSN 2050-4365 (Print)

ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

#### Criteria for inclusion in the Efficacy and Mechanism Evaluation journal

Reports are published in *Efficacy and Mechanism Evaluation* (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

#### **EME programme**

The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting 'science driven' studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: http://www.nets.nihr.ac.uk/programmes/eme

#### This report

The research reported in this issue of the journal was funded by the EME programme as project number 09/100/05. The contractual start date was in November 2010. The final report began editorial review in July 2015 and was accepted for publication in February 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2016. This work was produced by Hausenloy *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

### Efficacy and Mechanism Evaluation Editor-in-Chief

**Professor David Crossman** Bute Professor of Medicine and Dean and Head of Faculty of Medicine, University of St Andrews, and Honorary Consultant Cardiologist, NHS Fife Health Board, UK

### **NIHR Journals Library Editor-in-Chief**

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

### **NIHR Journals Library Editors**

**Professor Ken Stein** Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck** Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

**Professor Aileen Clarke** Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Director of NETSCC, HTA, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

**Professor Elaine McColl** Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie Health Services Research Unit, University of Aberdeen, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood** Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk